http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 09 Apr 2026 09:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 9, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that it has entered into an exclusive distribution agreement in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable microsphere for embolization.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html Thu, 09 Apr 2026 09:00:00 -0400 389650 389650 A.17150087 O.18972268 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 9, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that it has entered into an exclusive distribution agreement in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable microsphere for embolization.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html Thu, 09 Apr 2026 09:00:00 -0400 389650 389650 A.17150087 O.18972268 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 9, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that it has entered into an exclusive distribution agreement in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable microsphere for embolization.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html Thu, 09 Apr 2026 09:00:00 -0400 389650 389650 A.17150087 O.18972268 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 9, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that it has entered into an exclusive distribution agreement in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable microsphere for embolization.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html Thu, 09 Apr 2026 09:00:00 -0400 389650 389650 A.17150087 O.18972268 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 9, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that it has entered into an exclusive distribution agreement in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable microsphere for embolization.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html Thu, 09 Apr 2026 09:00:00 -0400 389650 389650 A.17150087 O.18972268 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 9, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that it has entered into an exclusive distribution agreement in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable microsphere for embolization.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html Thu, 09 Apr 2026 09:00:00 -0400 389650 389650 A.17150087 O.18972268 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 9, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that it has entered into an exclusive distribution agreement in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable microsphere for embolization.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html Thu, 09 Apr 2026 09:00:00 -0400 389650 389650 A.17150087 O.18972268 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 9, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that it has entered into an exclusive distribution agreement in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable microsphere for embolization.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html Thu, 09 Apr 2026 09:00:00 -0400 389650 389650 A.17150087 O.18972268 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 9, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that it has entered into an exclusive distribution agreement in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable microsphere for embolization.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html Thu, 09 Apr 2026 09:00:00 -0400 389650 389650 A.17150087 O.18972268 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 9, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that it has entered into an exclusive distribution agreement in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> with Asahi Intecc Co., Ltd., a global medical device company, for Nexsphere-F™, the company's novel fast-resorbable microsphere for embolization.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Exclusive+Distribution+Agreement+for+Nexsphere-F%E2%84%A2+in+Japan/26293036.html Thu, 09 Apr 2026 09:00:00 -0400 389650 389650 A.17150087 O.18972268 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <span value="Korea:389650" idsrc="xmltag.org" >NEXTBIOMEDICAL CO., LTD.</span> (KOSDAQ: 389650), an innovative medical device company based in <location value="LC/kr" idsrc="xmltag.org" >South Korea</location>, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from <span value="ACORN:1715008722" idsrc="xmltag.org" >Health Canada</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/NEXTBIOMEDICAL+Secures+Health+Canada+Approval+for+Nexsphere-F%E2%84%A2+in+Musculoskeletal+Pain+Embolization/25913053.html Thu, 29 Jan 2026 09:00:00 -0400 389650 389650 A.06822034 A.17150087 O.18972268 O.20026344 O.49223070 http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Announces+First+Patient+Enrolled+in+U.S.+FDA+Pivotal+Trial+of+Nexsphere-F%E2%84%A2+for+Knee+Osteoarthritis+Pain/25447579.html <div class="xn-content"> <ul type="disc"> <li> <i>RESORB Study Marks Major Step Toward <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Regulatory Approval and Global Commercialization</i> </li> http://www.streetinsider.com/Press+Releases/NEXTBIOMEDICAL+Announces+First+Patient+Enrolled+in+U.S.+FDA+Pivotal+Trial+of+Nexsphere-F%E2%84%A2+for+Knee+Osteoarthritis+Pain/25447579.html Mon, 13 Oct 2025 09:00:00 -0400 389650 389650 A.40249793 O.18972268 O.31407880